Product Center
Our company's technological and industrial innovation capabilities continue to be recognized
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-09
- Views:
(Summary description)Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.
Our company's technological and industrial innovation capabilities continue to be recognized
(Summary description)Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-09 09:07
- Views:
Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.


Innovation of Human Vaccine Technology Jiangsu Provincial Industrial Technology Engineering Center (under construction)
High tech enterprises are jointly evaluated and recognized by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation, with the aim of selecting and supporting enterprises that continue to conduct research and development and technology transfer in key high-tech fields supported by the state, and form core independent intellectual property rights. The certification standards and recognition procedures for high-tech enterprises are strict, with core independent intellectual property rights, scientific and technological achievement transformation ability, research and development organizational management level, and enterprise growth as the main assessment indicators. It is one of the most important and widely recognized national honors for Chinese technology enterprises.
The center will focus on the key technologies of vaccine research and industrialization in the development of the biological products industry in Jiangsu Province, targeting major infectious diseases such as influenza, chickenpox and shingles, respiratory syncytial virus, monkeypox, etc., to carry out the research and industrialization of new human vaccines. By utilizing AI technology to empower the entire process of vaccine design and development, anchoring international standards, breaking through key technologies such as large-scale virus cultivation and purification, mRNA vaccine preparation, and novel adjuvants, we aim to build advanced research and development platforms for large-scale virus amplification and purification, mRNA vaccines, novel vaccine adjuvants, and micro immunization research. Embrace the wave of intelligence and promote the upgrading of research and development work towards intelligence, precision, and efficiency.
The deep integration of technological innovation and industrial innovation is the core driving force for the company's development. In recent years, the company has continuously increased its investment in innovative research and talent development, and has made breakthroughs in platform and team building. It has been awarded multiple certifications such as "Jiangsu Postdoctoral Innovation Practice Base", "Taizhou Human Vaccine Engineering Research Center", and "Taizhou Innovative Virus Vaccine Engineering Technology Research Center"; The innovative talent team has also received recognition, including support from the National Key Talent Project Class A Talents and the Taizhou 113 Leading Talent Team Project.
The approval of the "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)" and the recognition as a "National High tech Enterprise" is an important manifestation of the company's commitment to the deep integration of scientific and technological innovation and industrial innovation. They not only signify our authoritative recognition of our full chain innovation capabilities in technology research and development, engineering scaling up, and industrialization landing, but also demonstrate our systematic layout of transforming cutting-edge technology into industrial strength. In the future, we will continue to promote the dual empowerment of technological breakthroughs and industrial applications, laying a solid foundation for innovation in the company's development. Based on the industrial ecology of China Medical City, we will contribute Zhonghui's strength to the high-quality development of Taizhou's pharmaceutical industry!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us